Trial Profile
A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Mardepodect (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 01 Nov 2019 Primary endpoint (Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4) has not been met as per the result published in the Journal of Clinical Psychopharmacology
- 01 Nov 2019 Results assessing Efficacy and safety of PF-02545920 Compared To Placebo in patients with Acute Exacerbation Of Schizophrenia published in the Journal of Clinical Psychopharmacology
- 10 Apr 2012 Actual patient number is 259 according to ClinicalTrials.gov.